The Simcyp® Simulator provides a framework for mechanistic Physiologically-Based Pharmacokinetic/Pharmacodynamic modelling of potentially interacting drugs. It also provides a scripting facility, using the Lua language, for developing customised pharmacodynamic and toxicity models driven by drug concentrations at the site of action.
Read MoreAuthors: Adrian Barnett
Simcyp Simulator within the DDMoRe Interoperability Framework—Proof of Concept Cases
Development of a Novel Multi-compartment Granuloma Model to Predict Local Drug Distribution and Its Impact on Pharmacodynamics and Disease Progression in Tuberculosis
Objectives: One of the hallmarks of pulmonary tuberculosis (TB) is the formation of granulomas, heterogeneous lesions composed of macrophage and neutrophil rich peripheral regions and a necrotic core, in the lungs of the infected host. Anti-TB drugs must penetrate these lesions to exert their effects. This work aimed to extend a permeability-limited lung model [1] […]
Read MoreApplication of Simcyp’s R Library Package in Simulation and Prediction of Metoprolol Compliance Using a Single Plasma Concentration Sample
The Simcyp Population-based Simulator: Architecture, Implementation, and Quality Assurance
Developing a user-friendly platform that can handle a vast number of complex physiologically based pharmacokinetic and pharmacodynamic (PBPK/PD) models both for conventional small molecules and larger biologic drugs is a substantial challenge. Over the last decade the Simcyp Population Based Simulator® has gained popularity in major pharmaceutical companies (70% of top 40 – in term […]
Read MoreThe Simcyp Population-based ADME Simulator
The Simcyp® population-based absorption, distribution, metabolism and excretion simulator is a platform and database for ‘bottom-up’ mechanistic modelling and simulation of the processes of oral absorption, tissue distribution, metabolism and excretion of drugs and drug candidates in healthy and disease populations. It combines experimental data generated routinely during preclinical drug discovery and development from in […]
Read More